ZURICH, Oct 7 (Reuters) - A Novartis AG drug, NVA237, had promising results in a mid-stage trial in patients with a progressive lung disease common among smokers, the Swiss drugmaker said on Tuesday. Once-daily treatment NVA237, which was licensed to Novartis in 2005 by Sosei Group Corp and Vectura Group Plc, provided 24-hour bronchodilation in patients with moderate-to-severe chronic obstructive pulmonary disease, or COPD.
